Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Diabetes

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798264

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798264

Sulfonylureas

PUBLISHED:
PAGES: 362 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Sulfonylureas Market to Reach US$10.8 Billion by 2030

The global market for Sulfonylureas estimated at US$9.7 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2024-2030. Diabetes Indication, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Other Indications segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 3.5% CAGR

The Sulfonylureas market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 3.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Sulfonylureas Market - Key Trends & Drivers Summarized

Sulfonylureas constitute a class of herbicides widely used to control broadleaf weeds and grasses in cereal crops, rice, vegetables, and turf. Noted for their ultra-low dosage rates-often just grams per hectare-these compounds inhibit ALS (acetolactate synthase), disrupting weed biosynthesis. Recent market evolution reflects a shift towards multiple-resistance weed populations, prompting the development of next-gen sulfonylureas with tailored selectivity, soil persistence, and safety profiles. Formulation improvements, such as micro-encapsulation and nanocarrier delivery, enhance soil targeting while reducing off-target movement.

Regulatory scrutiny over agrochemical residues has driven adoption of sulfonylureas with low-toxicity and rapid degradation pathways. Many agrochemical leaders now offer integrated packaging-combining sulfonylureas with pre-emergent herbicides in controlled-release blends. Digital spraying platforms and variable-rate applicators further improve precision, reducing environmental load while increasing efficacy.

How Are Biochemical and Resistance Challenges Being Tackled?

ultiple-resistance weeds-evolved to withstand several ALS inhibitors-have triggered investment in dual-mode herbicides combining sulfonylureas with unique active ingredients like synthetic auxins. Molecular design now includes functional groups that reduce weed metabolism and elongate treatment windows. Additionally, metabolic profiling and gene-expression analytics guide targeted compound optimization. Soil microbiome studies are enabling scientists to predict compound longevity and impact, ensuring safe use in sensitive regions.

Novel formulations featuring stabilized emulsions and biodegradable surfactants enhance root-zone delivery. These systems persist just enough to provide effective control, then break down swiftly, minimizing groundwater infiltration and meeting environmental standards.

Who Is Adopting These Solutions and Where?

igh-value crop growers in Asia-Pacific-particularly rice farmers in India, China, and Southeast Asia-depend heavily on selective sulfonylureas due to their efficiency and low cost per area. In Europe, integrated weed management programs favor low-dose, targeted use within crop rotation plans aiming to reduce seasonal herbicide volume. North American conservation agriculture systems use strip-tilled pre-emergent blends to maintain no-till systems while tackling persistent grassy weeds.

Emerging economies in Latin America and East Africa are adopting micro-pelletized sulfonylureas distributed via drone sprayers, ensuring uniform coverage and minimizing overlap. Agricultural service platforms now offer herbicide-as-a-service models, where farmers subscribe to scheduled drone or tractor rigs delivering optimized mixes seasonally.

The Growth in the Sulfonylureas Market Is Driven by Several Factors…

he market’s expansion stems from the need to control herbicide-resistant weed populations, driving innovation in dual-mode actives and dosage-efficient blends. Precision ag technologies-drone and GPS-sprayed micro-pellets-expand reach and minimize waste. Regulatory incentives for low-residue, fast-degrading agrochemicals encourage product reformulation. Crop intensification and double cropping practices in Asia increase application frequency. Finally, service-based delivery models reduce barriers to adoption among smallholder farmers in developing regions.

SCOPE OF STUDY:

The report analyzes the Sulfonylureas market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Diabetes Indication, Other Indications); Form (Tablet Form, Capsules Form, Other Forms); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GSK (GlaxoSmithKline)
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan (now part of Viatris)
  • Novartis International AG
  • Pfizer Inc.
  • Roche (Genentech subsidiary)
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila (Cadila Healthcare)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP39393

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sulfonylureas - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight Back on Affordable Oral Hypoglycemic Agents
    • Favorable Pricing and Established Safety Profiles Sustain Use of Sulfonylureas in Cost-Constrained Healthcare Systems
    • Generic Competition and Expiry of Patents Expand Access and Volume Sales in Emerging Economies
    • Integration into Combination Therapies Enhances Therapeutic Versatility in Type 2 Diabetes Treatment
    • Clinical Preference for Sulfonylureas in Initiation Therapy Maintains Relevance in Low-Resource Settings
    • Increased Demand for Step-Wise Treatment Protocols Drives Continued Role of Sulfonylureas in Sequential Therapy
    • Global Public Health Programs and WHO Essential Drug Listings Promote Adoption in National Formularies
    • Adoption of Value-Based Care Models Strengthens Business Case for Economical Diabetes Management Solutions
    • Comparative Cost Advantage Over New-Age Antidiabetics Preserves Market Share in Public Sector Institutions
    • Growing Investment in Patient Education and Adherence Support Reaffirms Sulfonylurea Prescriptions
    • Development of Modified-Release Formulations Improves Tolerability and Reduces Hypoglycemia Risk
    • Rising Use of e-Prescriptions and Clinical Decision Tools Supports Rational Sulfonylurea Utilization
    • Ongoing Pharmacovigilance and Real-World Evidence Studies Sustain Clinical Confidence in Legacy Drug Class
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sulfonylureas Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diabetes Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Tablet Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Capsules Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Sulfonylureas by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Sulfonylureas by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Sulfonylureas by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Sulfonylureas by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Sulfonylureas by Indication - Diabetes Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Sulfonylureas by Indication - Diabetes Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Sulfonylureas by Indication - Percentage Breakdown of Value Sales for Diabetes Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Sulfonylureas by Form - Tablet Form, Capsules Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Sulfonylureas by Form - Percentage Breakdown of Value Sales for Tablet Form, Capsules Form and Other Forms for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Sulfonylureas by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Sulfonylureas by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!